Despite the challenges the COVID-19 pandemic poses on many clinical trials, the phase 1b WHV138 trial is making great progress. By July 9, 2022, one third of Group 1 (N=7) has completed their vaccination regimen. Thanks to the highly experienced study team at the Brigham and Women’s Hospital, the WHV138 trial continues to progress well.
After this fourth and final vaccination for Group 1, which is 12 months post the first vaccination, the study participants will be followed for a 12-month safety observation period before they have officially completed the study. The remaining two thirds of volunteers in Group 1 are expected to complete their full course of vaccination by the end of August.
Group 2 is also making good progress. Participants in this group receive five vaccinations over the course of 8 months, also followed by the 12-month safety observation period. In this group, all volunteers have already received their first and second vaccination. The very final vaccination is anticipated to be administered in December 2022.
WHV is proud to be partnering with such an experienced clinical team and would like to acknowledge the remarkable contribution of volunteers in the middle of new COVID-19 waves in the country.
